TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00449514
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00449514
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00783393
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
Study: NCT04428411
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT01743482
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01906125
Drug: palbociclib capsule: phase 1 and 2 studies
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
Study: NCT01906125
Drug: Palbociclib capsule: phase 3 studies
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg dose of palbociclib. Formulation used in phase 3 studies
Study: NCT01906125
Drug: Palbociclib capsule: ICH
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg dose of palbociclib. Intended final market formulation
Study: NCT00309322
Drug: Phentolamine Mesylate (NV-101)
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01648257
Drug: GSK1265744 Free Acid Nanomilled Capsules
Normalized name: Defibrotide free acid
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
Study: NCT01648257
Drug: GSK1265744 Free Acid Micronized Capsules
Normalized name: Defibrotide free acid
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
Study: NCT05083455
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any rivaroxaban dispensing claim is used as the exposure group
Study: NCT05083455
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any enoxaparin dispensing claim is used as the reference group
Study: NCT00000335
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01405911
Drug: Placebo for Sitagliptin 25 mg
Normalized name: SITagliptin 25 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study: NCT01405911
Drug: Placebo for Sitagliptin 50 mg
Normalized name: SITagliptin 50 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study: NCT01405911
Drug: Sitagliptin 25 mg
Normalized name: SITagliptin 25 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study: NCT01405911
Drug: Sitagliptin 50 mg
Normalized name: SITagliptin 50 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study: NCT01535079
Drug: Strefen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration
Study: NCT01650376
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
Study: NCT01650376
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study: NCT01650376
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study: NCT00093028
Drug: CC-5013 (Revlimid™)
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A Study Complete
Study: NCT00093028
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: N/A Study Complete
Study: NCT01181479
Drug: Lessina crossover to AG200-15
Normalized name: phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
Study: NCT00019071
Drug: cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04124965
Drug: Rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT02430233
Drug: micronized progesterone 400 mg (Utrogestan)
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
Study: NCT01660542
Drug: Neoadjuvant Chemotherapy with Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
Study: NCT01428245
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
Study: NCT01428245
Drug: Estrace (estrogen)
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral estrace, 0.5-1 mg once a day for seven days
Study: NCT00874133
Drug: Motilium
Normalized name: Motilium
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg motilium thrice daily
Study: NCT04373733
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anti-viral
Study: NCT02193152
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04625972
Drug: AZD7442
Normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
Study: NCT00306488
Drug: OT-551 antioxidant eye drop
Normalized name: antioxidant 119
DrugBank: OT-551 (DB05650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
Study: NCT02641353
Drug: Apremilast Tablet
Normalized name: Apremilast Tablets
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg tablet
Study: NCT02641353
Drug: Apremilast Oral Suspension
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg oral suspension
Study: NCT02260622
Drug: rivaroxaban plus aspirin
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
Study: NCT02260622
Drug: clopidogrel plus aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
Study: NCT00086307
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
Study: NCT00086307
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
Study: NCT03208452
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Study: NCT03362593
Drug: Formulation without Active Drug
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation without Active Drug
Study: NCT01824004
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03277274
Drug: TAK-954
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-954 intravenous infusion.
Study: NCT01987908
Drug: Aes-103
Normalized name: Ae-turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
Study: NCT00003788
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003788
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003788
Drug: porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003788
Drug: procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01269333
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole 20mg for 7 days
Study: NCT01269333
Drug: fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluvoxamine 50mg for 7 days
Study: NCT00727064
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00727064
Drug: Venlafaxine Extended Release (VEN ER)
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03992144
Drug: Amoxicillin 500 Mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500mg an hour before tooth extraction
Study: NCT03992144
Drug: metronidazole 400mg
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg of metronidazole an hour before extraction
Study: NCT03992144
Drug: metronidazol 400mg and amoxicillin 500mg
Normalized name: metronidazole 400 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
Study: NCT03819699
Drug: Lu AF20513
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF20513 suspension for injection
Study: NCT01675700
Drug: Nitroglycerin patch
Normalized name: Nitroglycerin Patch
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 0.1 mg/hr patch
Study: NCT00346528
Drug: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT00346528
Drug: BSS Plus
Normalized name: BSS Plus
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT03090607
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic injection of saline
Study: NCT00110942
Drug: Systemic AMG 108
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SC AMG 108 Q4W for 3 doses
Study: NCT03711604
Drug: Tenalisib
Normalized name: Tenalisib
DrugBank: Tenalisib (DB15295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID Orally
Study: NCT00065143
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00065143
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02698098
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01307930
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
Study: NCT00928421
Drug: Polidocanol Endovenous Microfoam 0.125%
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol Endovenous Microfoam 0.125%, single dose
Study: NCT04359511
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone 0.7 mg/kg/d (PO)
Study: NCT00004859
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
Study: NCT02400255
Drug: Crenolanib besylate
Normalized name: mesylate
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01059344
Drug: Mesalamin
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.8g/day, 800 mg tablets
Study: NCT00599417
Drug: Bacterial Lysates
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
Study: NCT02159027
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc administered twice daily, dosage based on concomitant medication being taken.
Study: NCT03472508
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study: NCT01961544
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
Study: NCT00004859
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
Study: NCT00004859
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
Study: NCT01926392
Drug: water-soluble therapy
Normalized name: WATER SOLUBLE BASE
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study: NCT01926392
Drug: silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study: NCT00347490
Drug: Enoxaparine
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01379209
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered for GVHD prophylaxis as per institutional guidelines
Study: NCT03363035
Drug: Rivaroxaban 2.5 mg
Normalized name: rivaroxaban 2.5 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study: NCT03363035
Drug: Rivaroxaban 5 mg
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study: NCT03363035
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study: NCT05592197
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)
Study: NCT00517062
Drug: Growth hormone (Genotropin)
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
Study: NCT01739348
Drug: Verubecestat (Part I and Part II)
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 12 mg verubecestat tablet once daily, taken orally
Study: NCT01739348
Drug: Verubecestat (Part I and Part II)
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 40 mg verubecestat tablet once daily, taken orally
Study: NCT01739348
Drug: Verubecestat (Part I and Part II)
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 60 or 40 mg verubecestat tablet once daily, taken orally
Study: NCT01739348
Drug: Verubecestat (Part II)
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 40 mg verubecestat tablet once daily, taken orally
Study: NCT00294775
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01558063
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
Study: NCT01558063
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of saline given intravenously over 40 minutes.
Study: NCT02978482
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
Study: NCT02978482
Drug: tremelimumab + durvalumab
Normalized name: tremelimumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
Study: NCT00191516
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01807286
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I.
Study: NCT01807286
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
Study: NCT01807286
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
Study: NCT02417389
Drug: cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
Study: NCT02417389
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).